IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 284 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Article in PDF (366 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
  Introduction
  Conclusion
   Novel Carriers f...
   References

 Article Access Statistics
    Viewed7422    
    Printed164    
    Emailed8    
    PDF Downloaded735    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 


 
 Table of Contents    
REVIEW ARTICLE
Year : 2015  |  Volume : 81  |  Issue : 5  |  Page : 457-463

Recent advances in topical formulation carriers of antifungal agents


1 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Giza, Egypt
2 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

Date of Web Publication28-Aug-2015

Correspondence Address:
Dr. Eman Ahmed Bseiso
October 6 University, Giza
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.162328

Rights and Permissions

  Abstract 

Fungal infections are amongst the most commonly encountered diseases affecting the skin. Treatment approaches include both topical and oral antifungal agents. The topical route is generally preferred due to the possible side effects of oral medication. Advances in the field of formulation may soon render outdated conventional products such as creams, ointments and gels. Several carrier systems loaded with antifungal drugs have demonstrated promising results in the treatment of skin fungal infections. Examples of these newer carriers include micelles, lipidic systems such as solid lipid nanoparticles and nanostructured lipid carriers, microemulsions and vesicular systems such as liposomes, niosomes, transfersomes, ethosomes, and penetration enhancer vesicles.


Keywords: Carriers, formulation, fungal infections, skin


How to cite this article:
Bseiso EA, Nasr M, Sammour O, Abd El Gawad NA. Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol 2015;81:457-63

How to cite this URL:
Bseiso EA, Nasr M, Sammour O, Abd El Gawad NA. Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol [serial online] 2015 [cited 2019 Jun 17];81:457-63. Available from: http://www.ijdvl.com/text.asp?2015/81/5/457/162328



  Introduction Top


The incidence of cutaneous mycoses is increasing nowadays, especially in immunocompromised patients. They are classified according to the level of tissue invasion into superficial, cutaneous and subcutaneous mycoses. [1]

Superficial mycoses are caused by fungi that are limited to the outermost layers of the skin such as pityriasis versicolor, tinea nigra, and black/white piedra. When fungal infections extend deeper into the epidermis, they are termed as cutaneous mycoses or dermatomycoses; these can involve the skin appendages as well, such as hair and nails. Unlike superficial mycoses, cutaneous mycoses can induce cellular immune responses causing pathological changes. The fungi causing cutaneous mycoses are termed dermatophytes, and they usually belong to the following genera: Microsporum, Trichophyton, and Epidermophyton. Examples of the fungal diseases considered as dermatomycoses are tinea corporis, tinea pedis which is the most common form of dermatophytosis, tinea faciei, tinea manuum, tinea cruris, tinea barbae, and tinea capitis. [2],[3],[4]

If the infection further extends into the dermis and the subcutaneous tissue, it is then termed subcutaneous mycosis. The most common type of subcutaneous infection is sporotrichosis, caused by the fungus Sporothrix schenckii. Sporotrichosis is characterized by infiltrated nodular or ulcerated lesions on areas exposed to fungal inoculation. Other examples of subcutaneous mycoses include chromomycosis and maduramycosis (or mycetoma). [5]

Topical agents that are conventionally used for the treatment of skin fungal infections are usually formulated as creams, lotions or gels. [6] They either exhibit fungicidal or fungistatic actions depending on the agent being delivered. Since the side effects of fungal agents applied topically are less than their oral counterparts, they are the preferred agents. [7],[8],[9] Another advantage of topical formulation is that it avoids drug-drug interactions, which are more common in case of oral administration.

A drug must have some specific characteristics to be delivered in the form of a topical preparation for treatment of skin fungal infections; the most important of these is its lipophilic nature. When such a drug is applied on the skin, a depot is formed in the lipidic stratum corneum which releases the drug slowly to the underlying skin layers, that is, epidermis and dermis. Therefore, in order to achieve a topical effect for an antifungal drug, the release rate of this lipophilic drug should be controlled by the formulation in order to achieve high local therapeutic concentration and to provide prolonged pharmacological effect. [10] Another important consideration is the molecular weight of the drug; this is especially important for antifungal drugs known to exceed 500 Da such as amphotericin B and ketoconazole. These considerations have led to the development of several carriers which were found to improve topical drug delivery by either finding a way into a shunt such as hair follicle, accumulating between corneocytes, and intermingling with skin lipids, or by disintegrating and merging with lipidic layers. [11],[12] Whether their size was in the micrometer or nanometer range, carrier systems were found to impart desirable characteristics to topical formulations of antifungal drugs. Several carrier systems with their corresponding applications in the topical treatment of skin fungal infections will be discussed in this review.


  Novel Carriers for Treatment of Skin Fungal Infections Top


Micelles

A micelle is defined as a group of surfactant molecules dispersed in a liquid. In an aqueous solution, micellization occurs due to the mounting of hydrophilic head of surfactant molecules toward water and sequestering of the hydrophobic tails toward the inside. [13] Micelles were reported to be promising carriers for delivering an antifungal drug topically. [14]

Bachhav et al. developed new aqueous micellar solutions of clotrimazole, econazole nitrate, and fluconazole for the treatment of superficial fungal infections. [15] The micelles were prepared from novel amphiphilic methoxy poly(ethylene glycol)-hexyl substituted polylactide block copolymers. These micelles, which were in the nanometer range, showed superior entrapment for econazole nitrate. Upon topical application of the econazole micellar formula compared to the marketed Pevaryl ® cream on porcine skin, the deposition of econazole was found to be 13-fold higher in the former. This was attributed to the ability of the micellar solution to utilize the follicular penetration pathway. These findings suggest the promising role of micelles in improving the cutaneous bioavailability of the antifungal drug. [15]

Solid lipid nanoparticles and nanostructured lipid carriers

Solid lipid nanoparticles are carriers in which the drug is entrapped within a solid lipid core matrix. Examples of these lipids are triglycerides, diglycerides, monoglycerides, fatty acids, steroids, and waxes. [16] Nanostructured lipid carriers are the second generation of lipid nanoparticles in which the matrix is composed of a mixture of solid and liquid lipids. [17] Among the advantages of lipid nanoparticles are that the lipids utilized in their preparation are physiological lipids and that they can be prepared using organic solvent-free methods. [18] Both solid lipid nanoparticles and nanostructured lipid carriers have been recommended as good carriers for the treatment of topical skin infections, especially for antifungal drugs which are known to be lipophilic, and hence, can be successfully entrapped within the lipidic core of solid lipid nanoparticles or nanostructured lipid carriers. [19]

Souto et al. prepared solid lipid nanoparticles and nanostructured lipid carriers for the topical delivery of clotrimazole. [20] Both carriers were able to sustain its release for a period of 10 h, with solid lipid nanoparticles displaying occlusive property, which is desirable for topical application in general. [20] When solid lipid nanoparticles and nanostructured lipid carriers were used as topical carriers for ketoconazole, the latter was found to protect the drug against light degradation, conferring more stability to it and had comparable antifungal activity to the marketed product against Candida albicans. [21],[22] Solid lipid nanoparticles of miconazole incorporated in gel form were able to enhance its skin accumulation and uptake as compared to the marketed gel. [23] Further studies on miconazole solid lipid nanoparticles hydrogel displayed a sustained release for a period of 24 h and a 10-fold better skin retention of the drug compared to the suspension or the hydrogel form (without solid lipid nanoparticles). [24] Miconazole loaded in solid lipid nanoparticles form was found more efficient in the treatment of candidiasis, and hence, it was suggested by the authors as a promising formula to provide both quick relief as well as sustained release properties in addition to efficient in vivo performance in treating skin fungal infections. [24] Similarly, solid lipid nanoparticles were able to sustain the release of fluconazole for a period of 24 h and were able to localize the drug in the skin for better topical treatment of fungal infections. [25] However, nanostructured lipid carriers of fluconazole exhibited more than 3-fold higher retention in the skin compared to solid lipid nanoparticles. [26] Solid lipid nanoparticles of terbinafine were also found superior to the marketed product, with increased retention of the drug in rat skin. They also decreased the burden of C. albicans within a shorter period of time. [27],[28] The amount of terbinafine penetrating deep into the skin and reaching the dermis was higher for solid lipid nanoparticles compared to the marketed Lamisil ® cream. [29] Similar results were obtained with solid lipid nanoparticles of econazole. [30] Moreover, solid lipid nanoparticles of griseofulvin were shown to exhibit good skin permeation effect as manifested by the complete mycological and clinical cure in Microsporum canis infected guinea pigs upon administration of griseofulvin solid lipid nanoparticles gel twice daily for 8 days. [31]

Solid lipid nanoparticles and nanostructured lipid carriers were generally reported as effective in prolonging release of antifungal drugs and increasing their skin permeation; hence, they are considered amongst the most promising delivery systems. [32]

Microemulsions

Microemulsions are defined as thermodynamically stable mixtures of oil and water stabilized by surfactants and co-surfactants, with size in the nanometer range. Owing to their ability to solubilize many poorly soluble drugs, microemulsions have been found very promising in the delivery of antifungal drugs which are characterized by their lipophilicity. [33]

A microemulsion gel developed for topical delivery of fluconazole for the treatment of invasive fungal infections was developed and found very effective in enhancing percutaneous absorption of the drug. [34] Several researchers further confirmed the ability of microemulsions to increase percutaneous permeability of fluconazole. [35],[36] The same results were obtained with microemulsion formulae of ketoconazole, itraconazole, voriconazole, and econazole. [37],[38],[39],[40],[41] Microemulsion based hydrogel of clotrimazole exhibited higher skin retention and higher in vitro activity against C. albicans when compared to the conventional cream. [42] Furthermore, it demonstrated clinical efficacy when tested in patients suffering from tinea corporis, tinea circinata and tinea pedis with skin involvement of <10% of the total body surface area. [42] A microemulsion based hydrogel of sertaconazole showed 3-fold higher skin retention than the commercial cream, with higher in vitro antifungal activity against C. albicans. [43],[44] Amphotericin B was also incorporated in microemulsion form for treatment of invasive fungal infections in which a 2-fold increase in skin retention was obtained with the microemulsion formulation compared to the plain drug solution, with better in vitro antifungal activity against Trichophyton rubrum. [45] Moreover, microemulsion formulations of griseofulvin caused complete resolution of dermatophytosis in 7 days. [46]

Vesicular delivery systems

Vesicles are defined as highly ordered assemblies of one or several concentric lipid bilayers. They are formed when certain amphiphilic molecules such as phospholipids or surfactants are placed in water. They were first reported by Bangham in 1965. [47] As a topical drug carrier, vesicular systems act as penetration enhancers owing to the penetration of their lipidic components into the stratum corneum leading to alteration in the intercellular lipid matrix. They also serve as depots for localizing and sustaining the release of topically applied compounds. [48],[49] They were reported to reduce the systemic absorption of drugs owing to their high substantivity with the biological membranes. [50] Several vesicular systems have been prepared and successfully utilized in the treatment of skin fungal infections, among which are liposomes, niosomes, transferosomes, ethosomes, and penetration enhancer vesicles.

Liposomes

Liposomes are vesicles which consist of one or more concentric lipid bilayers separated by water or aqueous buffer compartments, ranging in size from 10 nanometers to 20 micrometers. [51],[52] Liposomes were reported to interact with the skin via several mechanisms. They are either adsorbed onto the skin surface leading to the release of drugs, or penetrate via the lipid-rich channels either intact, or after losing some lipid lamellae; alternatively, they form occlusive films which increase skin hydration and drug penetration into the stratum corneum. [53],[54]

Regarding their applications in fungal infections, a liposomal gel of ketoconazole allowed more drug retention in the skin compared to the gel and cream formulations. [55] They were also reported to increase both the deposition and skin permeation of fluconazole when compared to controls, and enhance its therapeutic effectiveness against cutaneous candidiasis. [56],[57] Liposomes were also able to effectively decrease fungal colonies when encapsulating ciclopirox olamine. [58] Prolongation of the action of terbinafine was also suggested by other authors upon encapsulating into liposomal gels. [59] Liposomes of croconazole too showed excellent activity against different fungal species when compared to miconazole cream as a control. [60]

Niosomes

Niosomes are similar to liposomes, they only differ in the replacement of phospholipids with non-ionic surfactants. [61],[62] Upon topical application, they interact with the stratum corneum leading to a reduction of transepidermal water loss. [63] Similar to liposomes, they are either adsorbed on the surface of the skin leading to high thermodynamic activity gradient of the drug at the interface which facilitates drug permeation, or they penetrate into the stratum corneum themselves and act as drug reservoirs. [64],[65],[66]

Regarding their applicability in the treatment of fungal infections, griseofulvin niosomes incorporated in gel showed high mycological cure rates of about 80% in patients suffering from tinea corporis. [67] Terbinafine hydrochloride niosomes showed efficacy against Aspergillus niger.[68] The action of ketoconazole was prolonged by encapsulating it into niosomes. [69] Niosomes of itraconazole and miconazole were also found to be effective, proving themselves to be effective carrier systems for antifungal drugs. [70],[71]

Transferosomes

Transferosomes, also termed as ultradeformable or flexible liposomes, have been used as carriers. They are formed of phospholipids and an edge activator; the latter is a surfactant having a high radius of curvature that destabilizes the phospholipid lipid bilayers and increases the deformability of vesicles. [72],[73] In addition to the mechanisms of penetration enhancement proposed for liposomes, transferosomes additionally have the ability to pass to deeper skin layers intact, owing to their deformability, driven by their ability to avoid dry surroundings.

Transferosomes of griseofulvin were found better than liposomes in the treatment of dermatophytosis, displaying complete mycological cure in 10 days. [74] They proved themselves as effective carriers for itraconazole as well. [75] A transferosomal formulation encapsulating amphotericin B was reported to be superior in its skin permeation and its antifungal activity against Trichophyton rubrum. [76] Transferosomal formulations of miconazole showed a higher rate of permeation of the drug into the deeper skin layers. [77]

Ethosomes

Ethosomes represent another type of deformable vesicles, which contain ethanol instead of edge activator in transferosomes as the penetration enhancer. Ethanol was reported to fluidize the intercellular lipids of the stratum corneum upon topical application and allow the easy penetration of vesicles into deeper skin layers. [78]

Ethosomes were found superior as carriers of clotrimazole and econazole. [79],[80] They were also reported to be clinically more effective than liposomes and the marketed econazole product against Candida. [81]

Penetration enhancer vesicles

Penetration enhancer containing vesicles are a new elastic vesicular system prepared by penetration enhancers with or without soybean lecithin. Penetration enhancers differ in their chemical structure and properties, the commonly used ones being oleic acid, Transcutol ® and Labrasol ® . [82]

Regarding their mechanism of action, penetration enhancer vesicles were reported to penetrate intact down to the epidermis, followed by further penetration to deeper layers owing to the enhancement of bilayers fluidity caused by the penetration enhancer. In addition, the free penetration enhancer exerts a synergistic effect through interaction with skin lipids, which leads to the perturbation of the intercellular skin lipid pathway improving the accumulation of drugs in deeper skin layers. [83]

We are aware of only one publication on the use of penetration enhancer vesicles in the treatment of skin fungal infections. Oleic acid vesicles loaded with fluconazole were shown to enhance the epidermal accumulation of the drug suggesting their potential for the treatment of deep localized skin fungal infections. [84]


  Conclusion Top


As time progresses, the need to develop new drug formulations increases. Conventional delivery systems, including creams, ointments, and gels are traditionally being used for the treatment of skin fungal infections, even if they are deep seated. Carrier systems have the ability to overcome the immediate drug release caused by these conventional formulations, hence they avoid the possibility of induction of allergic reactions. Moreover, they are especially customized to enhance the penetration of the antifungal agents, leading to more effective treatment of skin fungal infections, especially the deeper ones. These carrier systems are expected to slowly replace the conventional systems as more commercial preparations become available.

 
  References Top

1.
Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv 2010;7:1303-27.  Back to cited text no. 1
    
2.
Goldstein AO, Smith KM, Ives TJ, Goldstein B. Mycotic infections. Effective management of conditions involving the skin, hair, and nails. Geriatrics 2000;55:40-2, 45.  Back to cited text no. 2
    
3.
Zuber TJ, Baddam K. Superficial fungal infection of the skin. Where and how it appears help determine therapy. Postgrad Med 2001;109:117-20, 123.  Back to cited text no. 3
    
4.
Adams BB. Tinea corporis gladiatorum. J Am Acad Dermatol 2002;47:286-90.  Back to cited text no. 4
    
5.
Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am 2003;17:59-85, viii.  Back to cited text no. 5
    
6.
Güngör S, Erdal MS, Aksu B. New formulation strategies in topical antifungal therapy. J Cosmet Dermatol Sci Appl 2013;3:56-65.  Back to cited text no. 6
    
7.
Amichai B, Grunwald MH. Adverse drug reactions of the new oral antifungal agents - Terbinafine, fluconazole, and itraconazole. Int J Dermatol 1998;37:410-5.  Back to cited text no. 7
    
8.
Brodell RT, Elewski B. Antifungal drug interactions. Avoidance requires more than memorization. Postgrad Med 2000;107:41-3.  Back to cited text no. 8
    
9.
Gupta AK, Chow M, Daniel CR, Aly R. Treatments of tinea pedis. Dermatol Clin 2003;21:431-62.  Back to cited text no. 9
    
10.
Robert EM, Kalia YN. New developments in topical antifungal therapy. Am J Drug Deliv 2006;4:231-47.  Back to cited text no. 10
    
11.
Honeywell-Nguyen PL, Frederik PM, Bomans PH, Junginger HE, Bouwstra JA. Transdermal delivery of pergolide from surfactant-based elastic and rigid vesicles: Characterization and in vitro transport studies. Pharm Res 2002;19:991-7.  Back to cited text no. 11
    
12.
Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol 2004;123:168-76.  Back to cited text no. 12
    
13.
Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007;24:1029-46.  Back to cited text no. 13
    
14.
Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv Drug Deliv Rev 2001;47:113-31.  Back to cited text no. 14
    
15.
Bachhav YG, Mondon K, Kalia YN, Gurny R, Möller M. Novel micelle formulations to increase cutaneous bioavailability of azole antifungals. J Control Release 2011;153:126-32.  Back to cited text no. 15
    
16.
Utreja S, Jain NK, editors. Solid lipid nanoparticles. In: Advances in Controlled and Novel Drug Delivery. New Delhi: CBS Publishers; 2001. p. 408-25.  Back to cited text no. 16
    
17.
Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121-8.  Back to cited text no. 17
    
18.
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.  Back to cited text no. 18
    
19.
Muller RH, Radtke M, Souto EB. Nanostructured lipid carriers: A novel generation of solid lipid carriers. Pharm Technol Eur 2005;17:45-50.  Back to cited text no. 19
    
20.
Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71-7.  Back to cited text no. 20
    
21.
Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005;22:501-10.  Back to cited text no. 21
    
22.
Paolicellia P, Correntea F, Serricchioa D, Cerretoa F, Cesaa S, Titab B, et al. The system SLN-Dextran hydrogel: An application for the topical delivery of ketoconazole. J Chem Pharm Res 2011;3:410-21.  Back to cited text no. 22
    
23.
Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009;10:289-96.  Back to cited text no. 23
    
24.
Jain S, Jain S, Khare P, Gulbake A, Bansal D, Jain SK. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv 2010;17:443-51.  Back to cited text no. 24
    
25.
Gupta M, Tiwari S, Vyas SP. Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. Pharm Dev Technol 2013;18:550-9.  Back to cited text no. 25
    
26.
Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids 2012;165:454-61.  Back to cited text no. 26
    
27.
Vaghasiya H, Kumar A, Sawant K. Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride. Eur J Pharm Sci 2013;49:311-22.  Back to cited text no. 27
    
28.
Wavikar P, Vavia P. Nanolipidgel for enhanced skin deposition and improved antifungal activity. AAPS PharmSciTech 2013;14:222-33.  Back to cited text no. 28
    
29.
Chen YC, Liu DZ, Liu JJ, Chang TW, Ho HO, Sheu MT. Development of terbinafine solid lipid nanoparticles as a topical delivery system. Int J Nanomedicine 2012;7:4409-18.  Back to cited text no. 29
    
30.
Sanna V, Gavini E, Cossu M, Rassu G, Giunchedi P. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: In-vitro characterization, ex-vivo and in-vivo studies. J Pharm Pharmacol 2007;59:1057-64.  Back to cited text no. 30
    
31.
Aggarwal N, Goindi S. Preparation and in vivo evaluation of solid lipid nanoparticles of griseofulvin for dermal use. J Biomed Nanotechnol 2013;9:564-76.  Back to cited text no. 31
    
32.
Das S, Ng WK, Tan RB. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. II. Evaluation of the imidazole antifungal drug-loaded nanoparticle dispersions and their gel formulations. Nanotechnology 2014;25:105102.  Back to cited text no. 32
    
33.
Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev 2002;54 Suppl 1:S77-98.  Back to cited text no. 33
    
34.
El Laithy HM, El-Shaboury KM. The development of cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS PharmSciTech 2002;3:E35.  Back to cited text no. 34
    
35.
Shah RR, Magdum CS, Wadkar AK, Naikwade NS. Fluconazole topical microemulsion: Preparation and evaluation. Res J Pharm Technol 2009;2:353-7.  Back to cited text no. 35
    
36.
Salerno C, Carlucci AM, Bregni C. Study of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms. AAPS PharmSciTech 2010;11:986-93.  Back to cited text no. 36
    
37.
Patel MR, Patel BR, Parikh RJ, Bhatt KK, Solanki BA. Investigating the effect of vehicle on in-vitro skin permeation of ketoconazole applied in O/W micro emulsions. Acta Pharm Sci 2010;52:65-87.  Back to cited text no. 37
    
38.
Lee EA, Balakrishnan P, Song CK, Choi JH, Noh GY, Park GC, et al. Microemulsion-based hydrogel formulation of itraconazole for topical delivery. J Pharm Investig 2010;40:305-11.  Back to cited text no. 38
    
39.
Chudasama A, Patel V, Nivsarkar M, Vasu K, Shishoo C. Investigation of microemulsion system for transdermal delivery of itraconazole. J Adv Pharm Technol Res 2011;2:30-8.  Back to cited text no. 39
[PUBMED]  Medknow Journal  
40.
El-Hadidy GN, Ibrahim HK, Mohamed MI, El-Milligi MF. Microemulsions as vehicles for topical administration of voriconazole: Formulation and in vitro evaluation. Drug Dev Ind Pharm 2012;38:64-72.  Back to cited text no. 40
    
41.
Ge S, Lin Y, Lu H, Li Q, He J, Chen B, et al. Percutaneous delivery of econazole using microemulsion as vehicle: Formulation, evaluation and vesicle-skin interaction. Int J Pharm 2014;465:120-31.  Back to cited text no. 41
    
42.
Hashem FM, Shaker DS, Ghorab MK, Nasr M, Ismail A. Formulation, characterization, and clinical evaluation of microemulsion containing clotrimazole for topical delivery. AAPS PharmSciTech 2011;12:879-86.  Back to cited text no. 42
    
43.
Sahoo S, Pani NR, Sahoo SK. Microemulsion based topical hydrogel of sertaconazole: Formulation, characterization and evaluation. Colloids Surf B Biointerfaces 2014;120:193-9.  Back to cited text no. 43
    
44.
Sahoo S, Pani NR, Sahoo SK. Effect of microemulsion in topical sertaconazole hydrogel: In vitro and in vivo study. Drug Deliv 2014;1-8.[Epub ahead of print].  Back to cited text no. 44
    
45.
Butani D, Yewale C, Misra A. Amphotericin B topical microemulsion: Formulation, characterization and evaluation. Colloids Surf B Biointerfaces 2014;116:351-8.  Back to cited text no. 45
    
46.
Aggarwal N, Goindi S, Khurana R. Formulation, characterization and evaluation of an optimized microemulsion formulation of griseofulvin for topical application. Colloids Surf B Biointerfaces 2013;105:158-66.  Back to cited text no. 46
    
47.
Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52.  Back to cited text no. 47
    
48.
Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carrier: Dermal and transdermal drug delivery. J Control Release 1994;30:1-15.  Back to cited text no. 48
    
49.
Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol 2005;2:67-74.  Back to cited text no. 49
    
50.
Liu H, Pan WS, Tang R, Luo SD. Topical delivery of different acyclovir palmitate liposome formulations through rat skin in vitro. Pharmazie 2004;59:203-6.  Back to cited text no. 50
    
51.
Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 1995;12:229-46.  Back to cited text no. 51
    
52.
Bula D, Ghaly E. Liposome delivery systems containing ibuprofen. Drug Dev Ind Pharm 1995;21:1621-9.  Back to cited text no. 52
    
53.
Foldvari M, Gesztes A, Mezei M. Dermal drug delivery by liposome encapsulation: Clinical and electron microscopic studies. J Microencapsul 1990;7:479-89.  Back to cited text no. 53
    
54.
Elzainy AA, Gu X, Simons FE, Simons KJ. Hydroxyzine from topical phospholipid liposomal formulations: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. AAPS PharmSci 2003;5:E28.  Back to cited text no. 54
    
55.
Patel PR, Patel HH, Baria HA. Formulation and evaluation of carbopol gel containing liposomes of ketoconazole. Int J Drug Deliv Technol 2009;1:42-5.  Back to cited text no. 55
    
56.
Mitkari BV, Korde SA, Mahadik KR, Kokare CK. Formulation and evaluation of topical liposomal gel for fluconazole. Indian J Pharm Educ Res 2010;44:324-33.  Back to cited text no. 56
    
57.
Gupta M, Goyal AK, Paliwal SR, Paliwal R, Mishra N, Vaidya B, et al. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candidiasis. J Liposome Res 2010;20:341-50.  Back to cited text no. 57
    
58.
Verma ML, Palani S. Development and in-vitro evaluation of liposomal gel of ciclopirox olamine. Int J Pharma Bio Sci 2010;1:1-6.  Back to cited text no. 58
    
59.
Sudhakar B, Varma JN, Murthy KV. Formulation, characterization and ex vivo studies of terbinafine HCl liposomes for cutaneous delivery. Curr Drug Deliv 2014;11:521-30.  Back to cited text no. 59
    
60.
El-Badry M, Fetih G, Shakeel F. Comparative topical delivery of antifungal drug croconazole using liposome and micro-emulsion-based gel formulations. Drug Deliv 2014;21:34-43.  Back to cited text no. 60
    
61.
Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14.  Back to cited text no. 61
    
62.
Jaydeep DY, Priyanka RK, Kumar AV, Gurubas TS. Niosomes: A review. J Pharm Res 2011;4:632-6.  Back to cited text no. 62
    
63.
Junginger HE, Hofland HE, Bouwstra JA. Liposomes and niosomes interactions with human skin. Cosmet Toiletries 1991;106:45-50.  Back to cited text no. 63
    
64.
Fang JY, Yu SY, Wu PC, Huang YB, Tsai YH. In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm 2001;215:91-9.  Back to cited text no. 64
    
65.
Manosroi A, Wongtrakul P, Manosroi J, Sakai H, Sugawara F, Yuasa M, et al. Characterization of vesicles prepared with various nonionic surfactants mixed with cholesterol. Colloids Surf B Biointerfaces 2003;30:129-38.  Back to cited text no. 65
    
66.
Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 2005;59:485-90.  Back to cited text no. 66
    
67.
Kassem MA, Esmat S, Bendas ER, El-Komy MH. Efficacy of topical griseofulvin in treatment of tinea corporis. Mycoses 2006;49:232-5.  Back to cited text no. 67
    
68.
Sathali AA, Rajalakhmi G. Evaluation of transdermal targeted niosomal drug delivery of terbinafine hydrochloride. Int J PharmTech Res 2010;2:2081-9.  Back to cited text no. 68
    
69.
Shirsand S, Para M, Nagendrakumar D, Kanani K, Keerthy D. Formulation and evaluation of ketoconazole niosomal gel drug delivery system. Int J Pharm Investig 2012;2:201-7.  Back to cited text no. 69
    
70.
Ataei S, Moazeni E, Gilani K, Ghaffari A, Asgharian R, Najafabi A. In-vitro evalauation of itraconazole loaded vesicles prepared from non ionic surfactant. J Pharm Sci 2011;1:50-2.  Back to cited text no. 70
    
71.
Firthouse PU, Halith SM, Wahab SU, Sirajudin M, Mohideen SK. Formulation and evaluation of miconazole niosomes. Int J PharmTech Res 2011;3:1019-22.  Back to cited text no. 71
    
72.
Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1992;1104:226-32.  Back to cited text no. 72
    
73.
Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996;13:257-388.  Back to cited text no. 73
    
74.
Aggarwal N, Goindi S. Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of Microsporum canis - Dermatophytosis. Int J Pharm 2012;437:277-87.  Back to cited text no. 74
    
75.
Alomrani AH, Shazly GA, Amara AA, Badran MM. Itraconazole-hydroxypropyl-ß-cyclodextrin loaded deformable liposomes: In vitro skin penetration studies and antifungal efficacy using Candida albicans as model. Colloids Surf B Biointerfaces 2014;121:74-81.  Back to cited text no. 75
    
76.
Devi M, Kumar SM, Mahadevan N. Amphotericin-B loaded vesicular systems for the treatment of topical fungal infection. Int J Recent Adv Pharm Res 2011;4:37-46.  Back to cited text no. 76
    
77.
Pandit J, Garg M, Jain NK. Miconazole nitrate bearing ultraflexible liposomes for the treatment of fungal infection. J Liposome Res 2014;24:163-9.  Back to cited text no. 77
    
78.
Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 2000;65:403-18.  Back to cited text no. 78
    
79.
Maheshwari RG, Tekade RK, Sharma PA, Darwhekar G, Tyagi A, Patel RP, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: A comparative assessment. Saudi Pharm J 2012;20:161-70.  Back to cited text no. 79
    
80.
Verma P, Pathak K. Nanosized ethanolic vesicles loaded with econazole nitrate for the treatment of deep fungal infections through topical gel formulation. Nanomedicine 2012;8:489-96.  Back to cited text no. 80
    
81.
Bhalaria MK, Naik S, Misra AN. Ethosomes: A novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol 2009;47:368-75.  Back to cited text no. 81
    
82.
Mura S, Manconi M, Sinico C, Valenti D, Fadda AM. Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. Int J Pharm 2009;380:72-9.  Back to cited text no. 82
    
83.
Manconi M, Sinico C, Caddeo C, Vila AO, Valenti D, Fadda AM. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin. Int J Pharm 2011;412:37-46.  Back to cited text no. 83
    
84.
Zakir F, Vaidya B, Goyal AK, Malik B, Vyas SP. Development and characterization of oleic acid vesicles for the topical delivery of fluconazole. Drug Deliv 2010;17:238-48.  Back to cited text no. 84
    



This article has been cited by
1 Topical colloidal indocyanine green-mediated photodynamic therapy for treatment of basal cell carcinoma
Maha Fadel,Nevien Samy,Maha Nasr,Abdullah A. Alyoussef
Pharmaceutical Development and Technology. 2016; : 1
[Pubmed] | [DOI]
2 Novel nail penetration enhancer containing vesicles “nPEVs” for treatment of onychomycosis
Eman A. Bseiso,Maha Nasr,Omaima A. Sammour,Nabaweya A. Abd El Gawad
Drug Delivery. 2015; : 1
[Pubmed] | [DOI]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow